Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Q1 Losses Up on Higher Expenses, Lower Revenues

Premium

NEW YORK (GenomeWeb) – Alnylam Pharmaceuticals last week released its first-quarter financial results, posting a jump in its net loss amid lower revenues and higher expenses.

The company loss for the three-month period ended March 31 rose to $26.3 million or $0.39 a share, from $9 million, or $0.15 a share, in the year-ago quarter. This year's first quarter loss does not include a $224.7 million charge related to an in-process R&D expense tied to Alnylam's January acquisition of Merck's RNAi assets.

Revenues for the quarter dropped to $8.3 million from $18.6 million last year, primarily due to the recognition of deferred revenue in 2013 under a now-terminated collaboration with Cubist Pharmaceuticals in the area of respiratory syncytial virus.

R&D spending surged to $43.8 million from $22.2 million as Alnylam ramped up a number of drug programs. Meanwhile, general and administrative costs climbed to $8.9 million from $6.3 million amid increased business-development activities.

At the end of the first quarter, Alnylam had cash, cash equivalents, and marketable securities totaling $1 billion.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.